论文部分内容阅读
[目的]探讨格拉司琼联合胃复安预防肿瘤化疗后恶心呕吐的疗效及安全性。[方法]选择在某院接受化疗的肿瘤患者90例,分成观察组和对照组。对照组采用胃复安联合地塞米松。观察组采用格拉司琼联合胃复安。[结果]观察组总有效率为93.33%高于对照组总有效率68.89%,差异有统计学意义(P﹤0.01)。观察组出现便秘发生率为22.22%与对照组24.44%相比较,差异无统计学意义(P﹥0.05);观察组的失眠发生率为11.11%与对照组8.89%相比较,差异无统计学意义(P﹥0.05)。[结论]应用格拉司琼联合胃复安用于肿瘤化疗后恶心呕吐具有显著的预防效果,副作用少,建议临床进一步推广应用。
[Objective] To investigate the efficacy and safety of granisetron in combination with metoclopamine in preventing nausea and vomiting after chemotherapy. [Method] Ninety patients with cancer who underwent chemotherapy in a hospital were divided into observation group and control group. The control group with metoclopramide combined with dexamethasone. The observation group with granisetron combined metoclopramide. [Results] The total effective rate was 93.33% in the observation group and 68.89% in the control group, the difference was statistically significant (P <0.01). The incidence of constipation in the observation group was 22.22% compared with 24.44% in the control group, with no significant difference (P> 0.05). The incidence of insomnia was 11.11% in the observation group compared with 8.89% in the control group, with no significant difference (P> 0.05). [Conclusion] The combination of granisetron and metoclopramide has a significant preventive effect on nausea and vomiting after chemotherapy, with few side effects. It is suggested that it should be further popularized and applied clinically.